Subscribe to our Corporate and Science Update mailing list

Keep up to date with the latest research and developments from Diamond. Sign up for news on our scientific output, facility updates and plans for the future.

Subscribe here

Unravelling the mechanisms of immune escape by acute myeloid leukaemia

Acute myeloid leukaemia (AML) is a type of blood cancer that originates from white blood cells in the bone marrow. It is often fatal and is considered one of the most common cancers of children and the elderly. The high mortality rate associated with this cancer can partly be ascribed to ineffective current treatments, which consist of aggressive chemotherapy and stem cell transplantation. There is a great need to find alternative treatments for AML patients to improve their outcomes. By understanding the molecular mechanisms employed by AML cells to proliferate and avoid detection by the immune system, it is hoped this unmet need could be fulfilled.

Synchrotron Radiation Circular Dichroism (SRCD) spectroscopy at beamline B23 was used to probe the interactions of proteins involved in a molecular pathway responsible for AML immune escape. It was found that the pathway did not exist in healthy cells and was unique only to AML. The pathway results from a malignant transformation that involves the secretion of an immunoprotective protein, galectin-9, and the expression of a neuronal receptor, latrophilin 1, which triggers exocytosis upon interaction with other cells or soluble factors. The proteins help to impair parts of our immune system that try to destroy the cancer cells. Therefore, targeting this pathway could significantly enhance the patients’ immune defences and thus might be considered as a fundamentally new strategy for anti-AML therapy.

: Figure 1: Tim-3-dependent secretion of galectin-9 in human AML cells impairs the anti-leukemic activity of NK cells and cytotoxic T cells (based on Gonçalves Silva, I. et al.5).

Acute myeloid leukemia (AML) is an aggressive blood/bone marrow cancer originating from self-renewing malignant immature myeloid cells. AML rapidly becomes a systemic malignancy and is often a fatal disease since cancerous cells are suppressing anti-cancer immunity by impairing the functional activity of natural killer (NK) cells and T cells with cytotoxic activity¹.

A fundamental biochemical pathway² was discovered, which includes ligand-dependent activation of latrophilin 1, a neuronal receptor that facilitates exocytosis and is expressed in malignant but not healthy human myeloid cells³. This results in increased translation and secretion of the immune receptor Tim-3 and its ligand galectin-9. The process depends on activities of protein kinase C and mammalian target of rapamycin (mTOR). Tim-3 was found to have a dual role in the whole process by participating in galectin-9 secretion and by being released in a free soluble form. Galectin-9 impairs the anti-cancer activity of NK cells while free soluble Tim-3 attenuates secretion of interleukin-2 (IL-2) required for development of NK cell cytotoxic activity. These results were validated in ex vivo experiments using primary samples obtained from AML patients. Tim-3/galectin-9-dependent impairing of anticancer activity of cytotoxic lymphoid cells is summarised in Figure 1.

: Figure 2: Tim-3-galectin-9 interaction leads to significant conformational changes possibly increasing solubility of the protein complex. (A) The schematic structural models of galectin-9 (on the right) and extracellular domain of the Tim-3 (on the left). In the structural model of the Tim-3, amino acids involved in galectin-9-independent binding are highlighted using green colour. Amino acid residues of the Tim-3, which are potential targets for glycosylation, are highlighted using red colour. (B) The SRCD spectroscopy of galectin-9, Tim-3, and the complex made by both proteins. (Adapted from Gonçalves Silva, I. et al.2)

Synchrotron radiation circular dichroism (SRCD) spectroscopy at beamline B23 was used to characterise the secondary structure of Tim-3, galectin-9 and the complex made by these two proteins presented in Figure 2a. Structural organisation of both Tim-3 and galectin-9 are presented in the Figure 2a. It was found in earlier studies that galectin-9 interacts with non-glycosylated Tim-3 with high affinity (Kd = 2.8 × 10−8 M)4. However, this binding is further strengthened by interaction of galectin-9 with sugars of glycosylated Tim-3. In AML cells Tim-3 undergoes glycosylation2 which means that its affinity to galectin-9 is very high in AML cells. This assumption was confirmed by the fact that the complex is detectable by Western blot analysis, which suggests a strong high affinity binding between the two proteins2,5. SRCD spectroscopy was also applied to galectin-9 and Tim-3 mixed to a stoichiometry of 1:1 molar ratio (Fig. 2b). When mixed together with Tim-3, galectin-9 showed a CD spectrum which was clearly different from the simulated spectrum. This suggested that the interaction of Tim-3 with galectin-9 caused a conformational change of both proteins. An obvious increase in β-strand component was observed. Based on these findings, one may suggest that Tim-3 binding possibly alters the conformation of galectin-9. This results in increased capability of galectin-9 to interact with receptors in target cells. Galectin-9 is a protein, which contains two sugar-binding domains. Therefore, one domain could bind Tim-3 (or other proteins/receptor/trafficker) and leave the other domain open for interaction with a receptor molecule (for example Tim-3) associated with the plasma membrane of a target cell (for example NK cell or cytotoxic T cell).

This discovery opens new avenues for development of anti-leukaemia immunotherapy. Targeting this pathway might crucially enhance the patients’ immune defences helping them to eliminate leukaemia cells and could fundamentally change existing approaches to leukaemia diagnostics and anti-leukaemia therapy (and possibly the treatment of other cancers).

References

Khaznadar, Z. et al. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur. J. Immunol. 44, 3068–3080, doi:10.1002/eji.201444500 (2014).
Gonçalves Silva, I. et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine 22, 44-57, doi:10.1016/j.ebiom.2017.07.018 (2017).
Sumbayev, V.V. et al. Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukemia cells. Oncotarget 7, 45575–45583. doi:10.18632/oncotarget.10039 (2016).
Prokhorov, A. et al. The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukemia cells. Int. J. Biochem. Cell Biol. 59, 11–20. doi:10.1016/j.biocel.2014.11.017 (2015).
Gonçalves Silva, I. et al. The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells. Oncoimmunology 5, e1195535. doi: 10.1080/2162402X.2016.1195535 (2016).

Funding acknowledgement: This work was supported by a Daphne Jackson Trust postdoctoral fellowship, University of Kent Faculty of Sciences Research Fund. We thank Prof Giuliano Siligardi and Dr Rohanah Hussain for an excellent and fruitful collaboration and Diamond Light Source for access to B23 beamline (SM12578).

Corresponding author: Dr Vadim Sumbayev, Dr Inna M. Yasinska, Medway School of Pharmacy University of Kent, UK, V.Sumbayev@kent.ac.uk

Related publication

Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, Berger SM, Ushkaryov YA, Gibbs BF, Fasler-Kan E, Sumbayev VV. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine 22, 44 – 57, doi:10.1016/j.ebiom.2017.07.018 (2017).

Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.

Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE

See on Google Maps

Diamond Light Source^® and the Diamond logo are registered trademarks of Diamond Light Source Ltd

Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.

feedback

On this website

About Diamond

For Users

Industry

Science

Instruments

Press Office

Careers

Public

Procurement

Software & Tools

Social Diamond

Sub-navigation

In This Section

Sub Navigation

Subscribe to our Corporate and Science Update mailing list

Unravelling the mechanisms of immune escape by acute myeloid leukaemia

References

Related publication